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AbstrACt
background Numerous trials combining radiation therapy 
(RT) and immunotherapy in head and neck squamous cell 
carcinoma (HNSCC) are failing. Using preclinical immune 
cold models of HNSCC resistant to RT- immune checkpoint 
inhibitors, we investigate therapeutic approaches of 
overcoming such resistance by examining the differential 
microenvironmental response to RT.
Methods We subjected two HPV- negative orthotopic 
mouse models of HNSCC to combination RT, regulatory 
T cells (Treg) depletion, and/or CD137 agonism. Tumor 
growth was measured and intratumorous and lymph node 
immune populations were compared among treatment 
groups. Human gene sets, genetically engineered mouse 
models DEREG and BATF3–/–, flow and time- of- flight 
cytometry, RNA- Seq, Treg adoptive transfer studies, and in 
vitro experiments were used to further evaluate the role of 
dendritic cells (DCs) and Tregs in these treatments.
results In MOC2 orthotopic tumors, we find no 
therapeutic benefit to targeting classically defined 
immunosuppressive myeloids, which increase with RT. In 
these radioresistant tumors, supplementing combination 
RT and Treg depletion with anti- CD137 agonism stimulates 
CD103+ DC activation in tumor- draining lymph nodes 
as characterized by increases in CD80+ and CCR7+ 
DCs, resulting in a CD8 T cell- dependent response. 
Simultaneously, Tregs are reprogrammed to an effector 
phenotype demonstrated by increases in interferonγ+, 
tumor necrosis factorα+, PI3K+, pAKT+ and Eomes+ 
populations as well as decreases in CTLA4+ and NRP-1+ 
populations. Tumor eradication is observed when RT is 
increased to an 8 Gy x 5 hypofractionated regimen and 
combined with anti- CD25+ anti- CD137 treatment. In 
a human gene set from oral squamous cell carcinoma 
tumors, high Treg number is associated with earlier 
recurrence.
Conclusions Regulating Treg functionality and 
DC activation status within the lymph node is 
critical for generating a T cell effector response in 
these highly radioresistant tumors. These findings 
underscore the plasticity of Tregs and represent a new 
therapeutic opportunity for reprogramming the tumor 
microenvironment in HNSCCs resistant to conventional 
radioimmunotherapy approaches.
IntroduCtIon
The tumor microenvironment (TME) in 
HPV- negative head and neck squamous cell 
carcinoma (HNSCC) is known to be immu-
nologically cold,1 rendering them difficult 
to treat with immunotherapies, even when 
combined with radiation therapy (RT).2 3 
RT, a mainstay treatment for these tumors,4 
can increase immune infiltration and make 
these tumors vulnerable to immunotherapy5 
by promoting release of tumor antigens 
and danger- associated molecular patterns 
(DAMPs), increasing recruitment of antigen- 
presenting cells (APCs), and promoting 
their phagocytosis, thereby leading to T cell 
priming and antigen- specific recognition.6 
As an immunogenic T- cell response is elic-
ited, however, negative feedback mechanisms 
emerge to reduce effector T cell functions 
by recruitment of immunosuppressive regu-
latory T cells (Tregs) and myeloids to the 
radiated site by various cytokines.6 Methods 
to boost antitumor immunity induced by RT 
include strategies to counteract the immuno-
suppressive TME while recruiting and acti-
vating APCs and T cells, but such approaches 
vary depending on the TME.
In the current study, we report on how 
functional impairment of APC- Treg cross-
talk may improve response to RT in immu-
nologically cold preclinical HNSCC models 
characterized by poor T cell infiltration and 
poor therapeutic response to RT+ anti- PD- L1 
combination.7 8 In one model, we find that 
RT+ anti- PD- L1 evokes T cell infiltration 
followed by a wave of Treg recruitment driving 
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resistance that is overcome with Treg depletion strategies. 
In other similarly cold tumors, however, neither combi-
nation RT- immunotherapy nor RT- Treg depletion strate-
gies yield meaningful T cell infiltration or tumor growth 
response. Instead, RT elicits a strong myeloid reaction 
characterized by macrophage and myeloid- derived 
suppressor cell (MDSC) infiltration. Targeting these 
myeloid populations, however, yielded no therapeutic 
benefit. As many of these cells were MHC- II expressing, 
we focused instead on the effect of enhancing antigen 
presentation, particularly dendritic cell (DC) agonists, to 
improve therapeutic response to RT. Achieving a durable 
and persistent antitumorous response required targeting 
both DCs and Tregs in the context of RT, as neither 
doublet combination was sufficient. We find that addition 
of both, Treg depletion with anti- CD25 and DC agonism 
with anti- CD137, to RT is necessary to achieve meaningful 
therapeutic response. During the tumor rejection phase, 
an increase in DC frequency is observed in the draining 
lymph nodes (DLNs) accompanied with an increase in 
T cell effector function. Pharmacological blockade of 
lymphocyte egression from lymphoid organs prevented 
tumor regression indicating that antitumor T cells are 
induced in the secondary lymphoid organs during the 
immune response. Our data also highlight that repro-
gramming of Treg function, not numbers, is critical to 
achieving antitumor immune response and underscores 
the fragility of this population of cells. Finally, we observe 
that further augmentation of DC agonism with toll- like 
receptor (TLR) agonist failed to improve response rates. 
However, pulsing the RT in a hypofractionated manner 
with the presence of anti- CD25 Treg targeted therapy 
and anti- CD137 DC agonism can result in tumor eradi-
cation. While anti- CD25 and anti- CD137 interventions 
are currently underway in clinical trials, they are not yet 
studied in combination with RT. These data have signifi-
cant impact on clinical trial design for HNSCC resistant 
to conventional radioimmunotherapeutic approaches.
results
High tregs correlates with poor outcomes in oral cavity 
cancer, but response to treg targeted therapy in preclinical 
models varies by tumor type
We have previously demonstrated that expression of 
Treg associated genes, FOXP3, interleukin (IL)- 2RA and 
TGFB1, predict survival in HNSCC patients in TCGA.8 
Here, we interrogated RNA sequencing and clinical data 
from pretreatment tumors of 40 locally advanced patients 
with oral cavity cancer (online supplemental table 1).9 In 
the same manner as previously,8 two groups of 20 patients 
were classified as Treg high and Treg low based on Treg- 
related genes. A significant benefit in disease- free survival 
was observed with a trend towards significance for overall 
survival benefit in the Treg low group (figure 1A,B).
Targeting Tregs in the setting of RT has been demon-
strated to restore response to radioimmunotherapy 
treatment in immunologically cold preclinical models of 
HNSCC.7 8 However, the response rate to anti- CD25 deple-
tion varied by tumor model with a transient response in 
the MOC2 tumor model and incomplete intratumorous 
Treg depletion8 compared with near complete deple-
tion of intratumorous Tregs and eradication in the LY2 
tumors.8 We hypothesized that the failure to eradicate 
MOC2 tumors could have been due to a failure of the 
depleting antibody to penetrate the tumor. Therefore, 
we used the recently described anti- CD25 antagonistic 
antibody with optimized FCγR binding and antibody- 
dependent cell- mediated cytotoxicity, which has been 
shown to eradicate established tumors in subcutaneous 
models of colon and melanoma cell lines,10 by depleting 
Tregs in the tumor and not only in the blood and lymph 
nodes.10 In combination with RT (figure 1C), we again 
observed tumor eradication in LY2 (figure 1D), but, 
in contrast, only a small tumor growth regression was 
observed in the MOC2 tumors (figure 1E, online supple-
mental figure 1A,B).
To understand how these tumor models differ, we 
conducted cytometry by time of flight (CyTOF) of both 
tumor models at an early time point (3–4 days post- RT) 
compared with 0 Gy controls. Both models are T cell- 
poor, myeloid- rich tumors (online supplemental figure 
2A) in which T cell infiltration and activation appears to 
be unaffected by RT alone (online supplemental figure 
2A,B). To explore how resistance may be developing in 
MOC2 tumors, we also examined the composition of 
intratumorous infiltrates at a later time point (10 days 
post- RT). High- dimensional clustering showed a similarly 
low T cell content but revealed an increase in tumor- 
associated macrophages (TAMs) (figure 1F). We also 
analyzed the gene expression profiles of LY2 and MOC2 
tumors harvested 3 days and 7 days post- RT compared with 
0 Gy controls. Expression of several coinhibitory markers 
known to be expressed on Tregs11 appeared elevated or 
unchanged in late (d7 post- RT) MOC2 tumors, including 
CTLA4, PD-1, T cell immunoreceptor with Ig and ITIM 
domains (TIGIT), TIM3, LAG3 and GITR (figure 1G). 
These data suggest that Tregs in these tumor models may 
have a differing phenotype that can explain the differen-
tial effect to Treg- targeting strategies.
tumors resistant to treg targeted therapy with rt are myeloid 
dominated but do not respond to myeloid depletion strategies
Past analysis of Treg- depletion resistant tumors, such 
as the MOC2 tumors treated with RT +anti- CD25 anti-
body, showed persistent elevation of both macrophage 
and MDSC populations.8 These same populations were 
previously shown to decrease post- treatment in immu-
nologically cold tumors such as LY2 that nevertheless 
eradicate with Treg depletion strategies.8 CyTOF analysis 
confirmed large proportions of Gr-1+ and F4/80+ cells in 
both tumor models, with a particularly large proportion 
of Gr-1+ cells in MOC2 tumors pre and post- RT (figure 1F, 
online supplemental figure 2A). We, therefore, hypoth-
esized that pharmacological depletion of F4/80+ TAMs 
and Gr-1+ MDSCs may help overcome resistance to RT 
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Figure 1 High Tregs correlates with poor outcomes in oral cavity cancer, but response to Treg targeted therapy in preclinical 
models varies by tumor type and does not respond to myeloid depletion strategies. (A) Disease- free survival of 40 human OSCC 
patients, split into two cohorts Treg high (n=20) vs Treg low (n=20) based on combined median splits of normalized levels of 
FOXP3, IL- 2RA and TGFB1 transcript expression. (B) Overall survival of human OSCC patients, Treg high (n=20) vs Treg low 
(n=20). (C) Experimental procedure for RT +anti- CD25 treatment in LY2 and MOC2 tumor models. (D) Tumor growth curves 
for mice treated with RT (n=9) vs RT +anti- CD25 (n=10) in LY2 tumor model and replicate values 22 days postimplantation 
(p=0.0012, unpaired two- tailed t- test). (E) Tumor growth curves for mice treated with RT (n=9) vs RT +anti- CD25 (n=10) in 
MOC2 tumor model and replicate values 23 days postimplantation (p=0.0629 by unpaired two- tailed t- test). (F) t- SNE plots from 
CyTOF analysis of MOC2 tumors harvested 3 and 10 days post- RT compared with 0 Gy controls depicting expression of total 
singlet CD45+ cells; expression plot of MHC- II, CD11c, and F4/80; line chart for average proportion of TAM, DC, Treg and T 
cell populations (n=3 mice/group). (G) Heatmap of gene expression Z- scores of genes encoding costimulation and coinhibition 
markers from LY2 and MOC2 tumors harvested three or 7 days post- RT compared with 0 Gy controls (n=3 mice/group). (H) 
Experimental procedure for RT, anti- CSF1R, anti- CXCR2, anti- Gr-1 and/or anti- CD25 treatment in MOC2 tumor model. (I) Tumor 
growth curves for mice treated with RT, anti- CSF1R, anti- CXCR2, anti- Gr-1 and/or anti- CD25 in MOC2 tumor model (n=8 mice/
group). (J) Tumor growth curves for mice treated with RT, anti- Gr-1 and/or anti- CD25 in MOC2 tumor model (n=8 mice/group). 
(K) Proportion of CD45+CD3+CD4+Foxp3+ cells in MOC2 tumors harvested 13 days post- RT with RT +/–anti- CD25 treatment 
(n=5 mice/group). (L) Proportion of CD45+CD3+CD4+Foxp3+ cells in MOC2 tumors harvested 13 days post- RT with RT +/–
anti- CD25 treatment expressing indicated markers (n=5 mice/group, unpaired two- tailed t- test). CSF1R, colony- stimulating 
factor 1 receptor; CyTOF, cytometry by time- of- flight; DC, dendritic cell; IL-2, interleukin 2; RT, radiation therapy; TAM, tumor- 
associated macrophage; TGFB1, transforming growth factor-β 1; Treg, regulatory T cell; t- SNE, t- distributed stochastic neighbor 
embedding.
or RT +anti- CD25 treatment. We tested this hypothesis 
with depleting antibodies anticolony- stimulating factor 
1 receptor (CSF1R), anti- CXCR2 or anti- Gr-1 alongside 
RT, with or without anti- CD25 (figure 1H). There was no 
effect observed in tumor growth between depleted and 
non- depleted groups (figure 1I,J, online supplemental 
figure 1C,D), suggesting that, while prevalent, targeting 
these immune subsets had no effect on restoring anti-
tumor immunity in combination with RT in the MOC2 
model.
As Foxp3+ Tregs were still present in MOC2 tumors 
after Treg targeted therapy with RT+ anti- CD25 treatment 
(figure 1K), we aimed to assess their immunosuppressive 
function post- treatment. Several changes occurred in 
functional markers on these Tregs (figure 1L). A signif-
icant drop was observed in Treg CD69 expression, a 
marker associated with Treg development and suppres-
sive capability.12 This decrease was accompanied by 
trending decreases in Treg coinhibitory markers CTLA4 
and TIGIT (figure 1L). The expression of neuropilin 1 
(NRP-1), a marker of natural Tregs of thymic origin asso-
ciated with poor prognosis,13 also decreased significantly 
(figure 1L).
Myeloids are enriched in MHC-II and neither rt nor rt with 
treg depletion therapy is sufficient to enhance antigen 
presentation in myeloid-driven tumors
Given the failure to achieve any response with the addi-
tion of anti- CXCR2 and anti- CSFR1 treatments in various 
combinations (figure 1H–J), we refocused instead on 
examining the myeloid population within these tumors. 
We observed that many of these cells, including a 
number of TAMs, are MHC- II expressing (figure 1F), 
and reasoned that they were negatively targeted with 
myeloid depletion strategies. We hypothesized that while 
Treg suppressive function may be partially hindered by 
Treg- targeted therapy with RT+ anti- CD25, dysfunctional 
APCs in these myeloid- driven tumors were still failing to 
effectively prime conventional T cells necessary for tumor 
clearance. We focused on CD103+ DCs, as they have been 
previously demonstrated to function as transporters of 
antigens to the tumor draining lymph node (DLN), and 
therefore, essential for priming of tumor- specific CD8 T 
cells.14
RT alone, we observed, results in a slight decrease in 
the overall DC population 3 days post- RT while more 
readily sparing CD103+ DCs within that population 
(figure 2A–C), suggesting their relevance in early tumor 
surveillance in this model. We examined these DCs in the 
tumor and lymph nodes of MOC2 tumor- bearing mice 
after treatment with RT +anti- CD25 to see if any notable 
DC activation was occurring. No significant increase of 
MHC- II+ DCs or MHC- II+CD103+ DCs was observed in 
tumors or lymph nodes (figure 2D–G). In examining their 
functional status, no significant changes were observed in 
expression of costimulatory molecule CD80 nor in expres-
sion of CCR7(figure 2H,I), a marker on DCs indicative 
of enhanced antigen presentation15 as well as migratory 
capability.16 17 These data suggest no change in the matu-
rity or migratory ability of these DCs after RT +anti- CD25 
treatment. This conclusion is consistent with the observed 
lack of CD4 or CD8 T cell increases in tumors and lymph 
nodes (online supplemental figure 2C,D), as well as the 
lack of any increases in their expression of effector cyto-
kines interferon (IFN)γ or tumor necrosis factor (TNF)α 
(online supplemental figure 2E–H).
Adding dC agonists to tumors resistant to treg targeted 
therapy with rt reduces growth
To address the lack of conventional T cell and DC activa-
tion as well as the presence of these persistent Tregs, we 
considered the addition of a DC agonist to the backbone 
of Treg depleting therapy and RT. Targeting CD137 has 
been previously shown to assist in the clearance of various 
tumor models18–20 by modulating Tregs21 and DCs.22 
To assess CD137’s relevance in human HNSCC tumors, 
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Figure 2 Neither RT nor RT and Treg depletion therapy is sufficient to enhance antigen presentation in myeloid- driven tumors 
(A) proportion of CD45+F4/80–Ly- 6G–CD11c+MHC- II+ DCs from MOC2 tumors harvested 3 days post- RT compared with 0 Gy 
controls (n=4 mice/group, p=0.0126, unpaired two- tailed t- test). (B) Proportion of CD45+F4/80–Ly- 6G–CD11c+MHC- II+CD103+ 
DCs from MOC2 tumors harvested 3 days post- RT compared with 0 Gy controls (n=4 mice/group, p=0.2345, unpaired two- 
tailed t- test). (C) Proportion of CD45+F4/80–Ly- 6G–CD11c+MHC- II+CD103+ DCs from MOC2 tumors harvested 3 days post- RT 
compared with 0 Gy controls (n=4 mice/group, p=0.0008, unpaired two- tailed T test). (D) Proportion of CD45+F4/80–Ly- 6G–
CD11c+MHC- II+ DCs in MOC2 tumors harvested 9 days post- RT with RT +/–anti- CD25 treatment (n=4 mice/group, p=0.3016, 
unpaired two- tailed t- test). (E) Proportion of CD45+F4/80–Ly- 6G–CD11c+MHC- II+ DCs in MOC2 tumor draining lymph nodes 
harvested 9 days post- RT with RT +/–anti- CD25 treatment (n=5 mice/group, p=0.0904, unpaired two- tailed t- test). (F) Proportion 
of CD45+F4/80–Ly- 6G–CD11c+MHC- II+CD103+ DCs in MOC2 tumors harvested 9 days post- RT with RT +/–anti- CD25 treatment 
(n=4 mice/group). (G) Proportion of CD45+F4/80–Ly- 6G–CD11c+MHC- II+CD103+ DCs in MOC2 tumor draining lymph nodes 
harvested 9 days post- RT with RT +/–anti- CD25 treatment (n=5 mice/group). (H) Proportion of CD45+F4/80–Ly- 6G–CD11c+MHC- 
II+CD103+ DCs expressing CD80, CCR7 or PD- L1 in MOC2 tumors harvested 9 days post- RT with RT +/–anti- CD25 treatment 
(n=4 mice/group, unpaired two- tailed t- test). (I) Proportion of CD45+F4/80–Ly- 6G–CD11c+MHC- II+CD103+ DCs expressing CD80, 
CCR7 or PD- L1 in MOC2 tumor draining lymph nodes harvested 9 days post- RT with RT +/–anti- CD25 treatment (n=5 mice/
group). DCs, dendritic cells; LNs, lymph nodes; RT, radiation therapy.
we consulted a dataset hosted on the UCSC Single Cell 
browser23 and analyzed single cell RNA- Seq data from 18 
HNSCC patients. TNFRSF9 (CD137) is expressed particu-
larly highly in human Tregs (defined by cells high in CD4, 
FOXP3 and IL- 2RA expression), as well as in conven-
tional CD4 and CD8 T cells (online supplemental figure 
6). Similar CD137 expression was confirmed in MOC2 
tumors by flow cytometry, with its expression appearing 
highest in Foxp3+ Tregs compared with CD4 and CD8 
T cells, and complementary ligand CD137L expression 
appearing present on myeloid populations including 
F4/80–Ly6G–CD11c+ DCs and DCs expressing MHC- II 
(figure 3A).
We, therefore, hypothesized that utilizing the CD137 
agonistic antibody in the MOC2 model would reduce 
the regulatory effect of the Treg populations in the 
TME and also block deactivation of the DCs via CD137L 
reverse signaling, allowing for increased tumor surveil-
lance. Our data show that the combination of RT +anti- 
CD25+anti- CD137 treatment (figure 3B) resulted in 
significant tumor growth delay (figure 3C, online supple-
mental figure 1E). However, in the absence of anti- CD25, 
doublet combination of RT and anti- CD137 alone failed 
to reduce tumor growth in the MOC2 model (figure 3D, 
online supplemental figure 1F) or tumor eradication in 
the LY2 model (online supplemental figure 1G,H).
Given that RT is needed for release of DAMPs,6 we 
hypothesized that increasing the total dose of RT using 
a fractionated regimen might improve response. Addi-
tionally, a hypofractionated dose might enhance this 
therapy not only by increased cytotoxic cell kill, but also 
through a number of mechanisms by which the immune 
response is stimulated by RT.6 Hallmark pathways24 from 
RNA- sequenced tumors harvested 3 days post- RT showed 
significant increases in inflammatory response and IFNγ 
response pathways as well as apoptosis pathway (online 
supplemental figure 7A,B) in both LY2 and MOC2 
tumors, demonstrating this immune effect of RT. While 
a single 10 Gy fraction of RT+anti- CD25+anti- CD137 
did not result in tumor eradication in MOC2 tumors, it 
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Figure 3 Adding DC agonists to tumors resistant to Treg targeted therapy with RT reduces growth (A) histograms depicting 
CD137 expression in CD45+CD3+CD4+CD8+ T cells, CD45+CD3+CD4+Foxp3– T cells and CD45+CD3+CD4+Foxp3- Tregs and 
CD137L expression in CD45+CD11b– cells, CD45+CD11b+ cells, CD45+F4/80–Ly- 6G–CD11c+ cells and CD45+F4/80–Ly- 6G–
CD11c+MHC- II+ cells in MOC2 tumors harvested 9 days post- RT with only RT alone treatment. Each population is normalized 
to the same number of cells per histogram. (B) Experimental procedure for RT, anti- CD25 and anti- CD137 treatment in the 
MOC2 tumor model. (C) Tumor growth curves for mice treated with RT or RT+anti- CD25+anti- CD137 in the MOC2 tumor model 
and replicate values for all mice alive on day 27 postimplantation (n=8 mice/group, p=0.0013, unpaired two- tailed t- test). (D) 
Tumor growth curves for mice treated with RT, RT+anti- CD25 or RT+anti- CD137 in the MOC2 tumor model (n=8 mice/group). 
(E) Experimental procedure for hypofractionated RT, anti- CD25 and anti- CD137 treatment in the MOC2 tumor model. (F) Tumor 
growth curves for mice treated with hypofractionated RT+anti- CD25+anti- CD137 in the MOC2 tumor model in C57BL/6 mice 
(n=10 mice). DC, dendritic cell; RT, radiation therapy.
consistently delayed tumor growth in repeated experi-
ments. The same schedule, however, of antibody adminis-
tration given with 5 fractions of 8 Gy given over the course 
of 14 days (figure 3E), resulted in tumor eradication in 7 
of 10 mice (figure 3F).
Adding dC agonists reprograms tregs, induces a Cd4 and Cd8 
t cell -specific immunity, and enhances dC antigen presenting 
function in the dlns
The addition of anti- CD137 to RT+ anti- CD25 showed no 
significant change in the percent of intratumorous Tregs 
in the tumor or DLNs (figure 4A,B), but their surface 
marker expression included several significant changes. 
We observed significant intratumorous decreases in coin-
hibitory marker CTLA4, NRP-1 and a trending decrease 
in TIGIT expression (figure 4C), as well as a significant 
decrease in nodal expression of CD69 (figure 4D). RT+ 
anti- CD25+ anti- CD137 also showed increased effector 
function for Tregs. IFNγ and TNFα increased in Tregs in 
both tumor and lymph nodes (figure 4C,D), and these 
cytokines also exhibited increases systemically in the 
serum (figure 4E,F). Similarly, conventional T cell popu-
lations in tumor DLNs demonstrated increases in effector 
cytokines. Significant increases in IFNγ and TNFα expres-
sion in both Foxp3–CD4+ and CD8+ T cells were observed 
(figure 4G,H) alongside an increase in total proportion 
of CD4 T cells (figure 4I), suggesting T cell activation 
occurring in the lymph nodes.
These changes were accompanied by a significant 
increase in PI3K in intratumorous Tregs (figure 4C), a 
trending increase in phosphorylated Protein kinase B 
(pAKT) (figure 4C), as well as a significant increase in 
mean fluorescence intensity of T- box transcription factor 
Eomesodermin (Eomes) (figure 4J). Increased expres-
sion of Eomes after anti- CD137 administration has been 
demonstrated to play a role not only in CD8 and CD4 T 
cell -mediated cytotoxicity, but also in the reprogramming 
of Tregs to cytotoxic effectors.21 Given that these Tregs 
expressed increased effector cytokines in the tumor DLNs 
(figure 4D) and exhibited several changes in surface and 
intracellular markers in the tumor (figure 4C,J), these 
data suggest that a phenotypic switch occurred in Foxp3+ 
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Figure 4 Adding DC agonists reprograms Tregs, induces a CD4 and CD8 T cell -specific immunity, and enhances DC antigen 
presenting function in the draining lymph nodes (DLN). (A) Proportion of CD45+CD3+CD4+Foxp3+ Tregs in MOC2 tumors 
harvested 9 days post- RT with RT, anti- CD25 and/or anti- CD137 treatment (n=5 mice/group, one- way ANOVA with Tukey test). 
(B) Proportion of CD45+CD3+CD4+Foxp3+ Tregs in MOC2 tumor DLNs harvested 9 days post- RT with RT, anti- CD25, and/
or anti- CD137 treatment (n=5 mice/group, one- way ANOVA with Tukey test). (C) Proportion of CD45+CD3+CD4+Foxp3+ Tregs 
expressing CD69, CTLA4, TIGIT, NRP-1, CD137, IFNγ, TNFα, granzyme B, PI3K, or pAkt in MOC2 tumors harvested 9 days 
post- RT with RT, anti- CD25 and/or anti- CD137 treatment (n=5 mice/group, one- way ANOVA with Tukey test). (D) Proportion of 
CD45+CD3+CD4+Foxp3+ Tregs expressing CD69, IFNγ or TNFα in MOC2 tumor DLNs harvested 9 days post- RT with RT, anti- 
CD25 and/or anti- CD137 treatment (n=5 mice/group, one- way ANOVA with Tukey test). (E) Concentration of IFNγ from serum 
harvested 9 days post- RT with RT, anti- CD25, and/or anti- CD137 treatment (n=4 mice/group, one- way ANOVA with Tukey test). 
(F) Concentration of TNFα from serum harvested 9 days post- RT with RT, anti- CD25 and/or anti- CD137 treatment (n=4 mice/
group, one- way ANOVA with Tukey test). (G) Proportion of CD45+CD3+CD4+Foxp3– T cells expressing IFNγ or TNFα in MOC2 
tumor DLNs harvested 9 days post- RT with RT, anti- CD25, and/or anti- CD137 treatment (n=5 mice/group, one- way ANOVA 
with Tukey test). (H) Proportion of CD45+CD3+CD8+ T cells expressing IFNγ or TNFα in MOC2 tumor DLNs harvested 9 days 
post- RT with RT, anti- CD25, and/or anti- CD137 treatment (n=5 mice/group, one- way ANOVA with Tukey test). (I) Proportion 
of CD45+CD3+CD4+Foxp3– T cells and CD45+CD3+CD8+ T cells in MOC2 tumor DLNs harvested 9 days post- RT with RT, anti- 
CD25, and/or anti- CD137 treatment (n=5 mice/group, one- way ANOVA with Tukey test). (J) Mean fluorescence intensity of 
Tbet and Eomesodermin in CD45+CD3+CD4+Foxp3+ Tregs in MOC2 tumors harvested 9 days post- RT with RT, anti- CD25 and/
or anti- CD137 treatment (n=5 mice/group, one- way ANOVA with Tukey test). (K) Proportion of CD45+CD3+CD4+Foxp3– T cells 
and CD45+CD3+CD8+ T cells in MOC2 tumors harvested 9 days post- RT with RT, anti- CD25 and/or anti- CD137 treatment (n=5 
mice/group, one- way ANOVA with Tukey test). (L) Proportion of CD45+CD3+CD4+Foxp3– T cells expressing CD137 in MOC2 
tumors harvested 9 days post- RT with RT, anti- CD25, and/or anti- CD137 treatment (n=5 mice/group, one- way ANOVA with 
Tukey test). (M) Proportion of CD45+CD3+CD8+ T cells expressing CD137 in MOC2 tumors harvested 9 days post- RT with RT, 
anti- CD25 and/or anti- CD137 treatment (n=5 mice/group, one- way ANOVA with Tukey test). (N) Proportion of CD45+F4/80–Ly- 
6G–CD11c+MHC- II+ DCs in MOC2 tumor DLNs harvested 9 days post- RT with RT, anti- CD25, and/or anti- CD137 treatment (n=5 
mice/group, one- way ANOVA with Tukey test). (O) Proportion of CD45+F4/80–Ly- 6G–CD11c+MHC- II+CD103+ DCs expressing 
CD80, CCR7, or PD- L1 in MOC2 tumor DLNs harvested 9 days post- RT with RT, anti- CD25, and/or anti- CD137 treatment (n=5 
mice/group, one- way ANOVA with Tukey test). ANOVA, analysis of variance; DC, dendritic cell; IFNγ, interferon γ, RT, radiation 
therapy; TNF, tumor necrosis factor; Treg, regulatory T cell; pAKT, phosphorylated Protein kinase B.
While neither RT alone nor RT+ anti- CD25 increased 
T cell infiltration, the addition of anti- CD137 resulted 
in a significant increase of CD8 T cells in the tumor 
and an increasing trend for CD4 T cells (figure 4K). 
Both CD4 and CD8 T cells in the tumor showed signifi-
cantly decreased expression of CD137 (figure 4L,M). 
Anti- CD137 also had a notable effect on DCs, which 
increased significantly in the tumor DLNs (figure 4N). 
Additionally, the nodal CD103+ DC subset showed 
increases in CD80 and CCR7 expression (figure 4O), 
suggesting increased maturity, migratory ability and 
presentation compared with both RT alone and RT+an-
ti- CD25 groups.
tumor growth delay effect with the addition of dC agonist is 
dependent on Cd8 t cells and t cells’ ability to egress from 
the lymph nodes but is not enhanced with the addition of tlr 
agonist
To test the dependence of the therapeutic effect that RT 
+anti- CD25+anti- CD137 has on T cell- mediated immu-
nity, we treated the mice with upfront depleting anti-
bodies to CD4, CD8, or both T cell populations prior 
to the administration of RT +anti- CD25+anti- CD137 
treatments (figure 5A). Depleting CD4 and CD8 T cells 
or CD8 T cells alone, a significant increase in tumor 
growth was observed (figure 5B, online supplemental 
figure 1I). Depletion of CD4 T cells alone resulted in 
a trending increase in tumor growth, but this differ-
ence did not appear until 13 days postimplantation 
(figure 5B, online supplemental figure 1I). These find-
ings suggest a strong dependence on CD8 T cells for 
tumor control at all stages, with possible dependence 
also exhibited by CD4 T cells.
Given the stimulatory effect of treatment on CD80 and 
CCR7 expression on MHC- II+CD103+ DCs, we sought to 
test whether presentation in the lymph nodes by DCs was 
necessary for tumor growth delay. We used Fingolimod 
hydrochloride (FTY720), which prevents antigen- primed 
T cells from egressing from the lymph nodes, to prevent 
any activated T cell populations from migrating to the 
tumor site and exerting effector functions. Additionally, 
for clinical relevance, we administered anti- PD- L1 anti-
body alongside treatment to seek further tumor clearance. 
The addition of anti- PD- L1 only added a marginal benefit 
in tumor clearance (figure 5C,D, online supplemental 
figure 1J). Notably, however, the addition of FTY720 
completely reversed the benefit of treatment, with tumor 
sizes remaining nearly identical to mice treated with RT 
alone (figure 5D, online supplemental figure 1J). These 
findings suggest that T cells egressing from the lymph 
nodes play a key role in RT +anti- CD25+anti- CD137 
therapy.
After demonstrating the importance of T cell- 
mediated effects of RT+anti- CD25+anti- CD137 treat-
ment, we sought to determine whether enhancing DC 
uptake of tumor antigen would further promote T cell 
effector function. We used Poly:IC, a synthetic dsRNA 
known to stimulate TLR3 (a TLR present on DCs) to 
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Figure 5 Tumor growth delay effect with the addition of DC agonist is dependent on CD8 T cells, T cells’ ability to egress 
from the lymph nodes, but is not enhanced with the addition of TLR agonist (A) experimental procedure for RT, anti- CD25, anti- 
CD137, anti- CD4, and anti- CD8 treatment in the MOC2 tumor model. (B) Tumor growth curves for mice treated with RT+anti- 
CD25+anti- CD137 alone or with anti- CD4, anti- CD8 or anti- CD4+anti- CD8 in the MOC2 tumor model and replicate values 
for all mice alive on day 21 postimplantation (n=13 mice/group on day 0, one- way ANOVA with Tukey test). (C) Experimental 
procedure for RT, anti- CD25, anti- CD137, anti- PD- L1, and FTY720 treatment in the MOC2 tumor model. (D) Tumor growth 
curves for mice treated with RT, RT+anti- CD25, RT+anti- CD25+anti- CD137, RT+anti- CD25+anti- CD137+anti- PD- L1 or RT+anti- 
CD25+anti- CD137+anti- PD- L1+FTY720 in the MOC2 tumor model and replicate values for all mice alive on day 34 post- 
implantation (n=8 mice/group on day 0, one- way ANOVA with Tukey test). (E) Experimental procedure for RT, anti- CD25, anti- 
CD137, and Poly:IC treatment in the MOC2 tumor model. (F) Tumor growth curves for mice treated with RT, RT+anti- CD25+anti- 
CD137, or RT+anti- CD25+anti- CD137+Poly:IC in the MOC2 tumor model. Tumor volumes bar chart for all mice alive on day 
14 post- implantation (n=9 mice/group on day 0, one- way ANOVA with Tukey test). ANOVA, analysis of variance; RT, radiation 
therapy; TLR, toll- like receptor.
stimulate DCs and activate T cell immunity, and we 
used additional fractions of RT to stimulate cancer cell 
damage and antigen release. Addition of Poly:IC to 
RT+anti- CD25+anti- CD137 therapy revealed no signifi-
cant additional tumor growth delay (figure 5E,F, online 
supplemental figure 1K).
both dCs and tregs are required for functional dC agonism 
with anti-Cd137
To test the hypothesis that anti- CD137 affects both 
Tregs and DCs to stimulate their respective differenti-
ation toward reprogrammed effector T cells and acti-
vated, antigen- presenting DCs, we conducted targeted 
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Figure 6 Both DCs and Tregs are required for functional DC agonism with anti- CD137 (A) experimental procedure for RT, anti- 
CD25 and anti- CD137 treatment in the MOC2 tumor model using BATF3–/– mice and wildtype controls. (B) Tumor growth curves 
for mice treated with RT +anti- CD25+anti- CD137 in BATF3–/– mice versus wildtype controls in the MOC2 tumor model and 
replicate values for all mice alive on day 13 postimplantation (n=9 mice/group on day 0, one- way ANOVA with Tukey test). (C) 
Proportion of CD45+CD3+CD4+Foxp3– T cells or CD45+CD3+CD8+ T cells in MOC2 tumors from BATF3–/– mice versus wild- type 
controls 15 days post- RT with RT +anti- CD25+anti- CD137 treatment (n=4 mice/group, two- tailed unpaired t- test). (D) Proportion 
of CD45+CD3+CD4+Foxp3+ Tregs in MOC2 tumors from BATF3–/– mice versus wild- type controls 15 days post- RT with RT 
+anti- CD25+anti- CD137 treatment (n=4 mice/group, two- tailed unpaired t- test). (E) Proportion of CD45+CD3+CD4+Foxp3+ Tregs 
in MOC2 tumors from BATF3–/– mice versus wild- type controls expressing NRP-1, CD137, IFNγ, TNFα, PI3K or pAkt 15 days 
post- RT with RT +anti- CD25+anti- CD137 treatment (n=4 mice/group, two- tailed unpaired t- test). (F) Experimental procedure 
for RT, anti- CD25, anti- CD137 and dT treatment in the MOC2 tumor model using DEREG mice. (G) Tumor growth curves for 
mice treated with RT, DT, RT +DT, or RT +DT + anti- CD137 versus untreated controls in the MOC2 tumor model in DEREG mice 
and replicate values for all mice alive on day 22 postimplantation. (n=8 mice/group on day 0, one- way ANOVA with Tukey test). 
(H) Proportion of CD45+CD3+CD4+Foxp3– T cells or CD45+CD3+CD8+ T cells in MOC2 tumors from DEREG mice harvested 20 
days post- RT with RT (n=5), dT (n=4), RT +DT (n=5) or RT +DT + anti- CD137 (n=4) treatments vs untreated controls (n=5). (I) 
Proportion of CD45+CD11c+MHC- II+ DCs in MOC2 tumors or tumor draining lymph nodes (LN) from DEREG mice harvested 
8 days post- RT with RT +anti- CD25+anti- CD137 or RT +DT + anti- CD137 treatment (n=6 mice/group, two- tailed unpaired t- 
test). (J) Proportion of CD45+CD11c+MHC- II+CD103+ DCs in MOC2 tumors or tumor draining LNs from DEREG mice harvested 
8 days post- RT with RT +anti- CD25+anti- CD137 or RT +DT + anti- CD137 treatment (n=6 mice/group, two- tailed unpaired 
t- test). (K) Proportion of CD45+CD11c+MHC- II+CD103+CD80+ DCs in MOC2 tumors or tumor draining LNs from DEREG mice 
harvested 8 days post- RT with RT +anti- CD25+anti- CD137 or RT +DT + anti- CD137 treatment (n=6 mice/group, two- tailed 
unpaired T test). ANOVA, analysis of variance; DC, dendritic cell; IFNγ, interferon γ; ns, not significant; RT, radiation therapy; 
TNFα, tumor necrosis factor α; Treg, regulatory T cell.
depletion of the relevant compartments using genet-
ically engineered animal models. We first tested RT 
+anti- CD25+anti- CD137 in BATF3–/– mice to test the 
dependence of DCs on therapeutic efficacy (figure 6A). 
These mice have abolished BATF3 gene function and are 
deficient in BATF3- dependent, CD8+ cross- presenting 
conventional DCs and therefore are highly relevant to 
this CD8 T cell -dependent therapy. Treated BATF3–/– 
mice had significantly larger tumors by days 10 and 13 
postimplantation compared with WT (figure 6B, online 
supplemental figure 1L).
Analyzing flow cytometry on intratumorous popu-
lations, we observed that CD4 T cells trended toward a 
decrease, while CD8 T cell infiltration decreased signifi-
cantly in BATF3–/– mice (figure 6C). CD4+Foxp3+ Treg 
infiltration appeared unchanged. (figure 6D), and their 
expression of surface markers NRP-1 and CD137 and intra-
cellular markers IFNγ, TNFα, PI3K, and pAKT did not 
significantly change (figure 6E). The observed decrease 
of T cell infiltration in the DC- deficient BATF3–/– mice 
confirms that RT +anti- CD25+anti- CD137 stimulation of 
conventional T cell tumor infiltration is dependent on 
DCs, and the lack of reversal of the Treg phenotype switch 
suggests that this treatment may be sufficient to induce 
these changes in Treg phenotype intrinsically.
We next asked whether ablation of Treg populations 
would likewise reverse the tumor growth delay seen in 
RT +anti- CD25+anti- CD137 therapy. Anti- CD25 caused 
several changes in intratumorous Treg populations 
(figure 1L) but did not decrease the total proportion 
of Foxp3+ Tregs in the tumor (figure 1K). We chose to 
substitute this anti- CD25 antibody with genetic ablation 
of Treg populations to test whether complete Treg deple-
tion would aid in tumor clearance. At the same time, this 
would isolate the effect of targeting Tregs while avoiding 
any effects that anti- CD25 might have on cell populations 
other than Tregs. We used DEREG mice expressing diph-
theria toxin receptor upstream of the FOXP3 promoter 
to fully deplete Tregs from the mice. We proceeded with 
tumor implantation, substituting anti- CD25 therapy with 
administration of diphtheria toxin (DT). We chose to test 
Treg depletion alongside RT as well as with the addition 
of anti- CD137 (figure 6F).
While the addition of DT did not delay tumor growth 
compared with RT alone, notably, the addition of anti- 
CD137 to RT+DT did not improve response (figure 6G, 
online supplemental figure 1M). We hypothesized that 
complete ablation of Tregs reversed the stimulatory effect 
of anti- CD137 on Tregs, as a TME devoid of Tregs elimi-
nates the possibility of reprogrammed Tregs aiding in the 
immune response or interacting with DCs. Analysis by flow 
cytometry showed no significant changes in CD4 or CD8 
T cell infiltration with the substitute of DT for anti- CD25 
(figure 6H). We also compared RT+DT + anti- CD137- 
treated DEREG mice with RT+anti- CD25+anti- CD137 
treated mice to test for any changes in DC populations. 
A significant decrease in MHC- II+DCs was observed in 
lymph nodes with a trend down decrease in the tumor 
(figure 6I), no change was observed in intratumorous 
MHC- II+CD103+DCs (figure 6J), and a trending decrease 
was observed in lymph node MHC- II+CD103+DCs 
(figure 6J). No change was observed in CD80 expres-
sion on MHC- II+CD103+DCs in tumor or lymph nodes 
(figure 6K).
While RT +anti- CD25+anti- CD137 resulted in tumor 
growth delay compared with RT in previous experi-
ments, substituting anti- CD25 with complete deple-
tion of Tregs using DT reversed both T cell infiltration 
(figure 6H) as well as tumor growth delay (figure 6G, 
online supplemental figure 1M). The use of DT in place 
of anti- CD25 resulted in a decrease in DCs (figure 6I) 
but resulted in no change in the expression of CD80 on 
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Figure 7 RT +anti- CD25+anti- CD137 is sufficient to reprogram Tregs into cytokine- producing cytolytic effectors. (A) 
Experimental procedure for adoptive transfer by tail vein injection of GFP+ Tregs from non- tumor- bearing DEREG mice into 
MOC2 tumor- bearing RAG1–/– mice followed by RT+anti- CD25+anti- CD137 treatment and harvesting of tumors for flow 
cytometric analysis. (B) Proportion of CD45+CD4+Foxp3+GFP+ Tregs expressing TNFα, IFNγ, or Perforin in MOC2 tumors from 
RAG1–/– mice following adoptive transfer of Tregs from DEREG mice and treatment of RT+anti- CD25+anti- CD137 harvested 
9 days post- RT versus RT alone controls (n=7 mice/group, two- tailed unpaired T test). (C) Mean fluorescence intensity of 
Eomesodermin in CD45+CD4+Foxp3+GFP+ Tregs in MOC2 tumors from RAG1–/– mice following adoptive transfer of Tregs from 
DEREG mice and treatment of RT+anti- CD25+anti- CD137 harvested 9 days post- RT versus RT alone controls (n=7 mice/group, 
two- tailed unpaired t test). (D) Experimental procedure for Treg cytolytic assay using GFP+ Tregs harvested from tumor- bearing 
DEREG mice harvested 8 days post- RT with 10 Gy and MOC2 cells irradiated with 10 Gy 72 hours prior and stained with cell 
Tracker red. Cells were cultured in conditioned media from irradiated MOC2 cells with an 2:1 effector to target ratio for 4 hours 
at 37°C prior to detection of live cells by live/dead aqua viability dye. (E) Proportion of live MOC2 cells after incubation with 
Tregs harvested from tumor- bearing DEREG mice treated with IL-2 and anti- CD137 (n=4) compared with IL-2 and matching 
isotype control antibody (n=3). Each point represents technical replicates (p=0.0548, two- tailed unpaired t test). IFNγ, interferon 
γ; IL-2, interleukin 2; RT, radiation therapy; TNFα, tumor necrosis factor α; Treg, regulatory T cell.
DCs (figure 6K). Taken together, these data suggest anti- 
CD137 modulates the CD137–CD137L action between 
Tregs and DCs. This is evidenced by the fact that abla-
tion of the relevant populations in the BATF3–/– and 
DEREG models reverses the tumor delaying effects of 
anti- CD137 in the context of RT. While anti- CD137 may 
still induce some changes in Treg and DC phenotype, 
both populations are needed to translate to an activated 
CD8 T cell response.
rt + anti-Cd25 + anti-Cd137 is sufficient to reprogram tregs 
into cytokine-producing cytolytic effectors
The substitution of anti- CD25 for complete ablation of 
Tregs with DT highlighted to importance of Tregs in the 
benefit of RT +anti- CD25+anti- CD137 therapy. Given 
these results, we sought to confirm that anti- CD137 acted 
specifically on Tregs. Considering that PI3K, pAKT, and 
transcription factor Eomes were increased in Tregs in 
addition to their increased production of IFNγ and TNFα 
(figure 4C,J), we also wanted to test the hypothesis that 
these cells had cytolytic function to aid in tumor clearance, 
as shown in other studies involving CD137 agonism.18 21 
MOC2 tumors were implanted in RAG-1–/– mice, which 
completely lack functional T cells, and then were adop-
tively transferred GFP+ Tregs from untreated DEREG 
mice (figure 7A). RT +anti- CD25+anti- CD137 treatment 
was administered compared with RT alone to test the 
hypothesis that Foxp3+ Tregs were being converted to 
cytolytic effectors.
Intratumorous Tregs in treated mice expressed signifi-
cantly higher levels of IFNγ and TNFα effector cytokines 
(figure 7B). Tregs in treated mice expressed significantly 
higher expression of Perforin, suggesting a polariza-
tion to a cytolytic function in these Tregs (figure 7B). 
Tregs also showed higher mean fluorescence intensity 
of Eomes, suggesting that these changes in cytotoxicity 
were associated with a phenotypic change in the Tregs 
(figure 7C). These data were indicative of Treg fragility, 
whereby CD4 T cells retaining FoxP3 expression can 
function to enhance cancer cell kill.13 To further examine 
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this cytotoxic phenotype, we cultured live GFP+ Tregs 
from MOC2 tumor- bearing DEREG mice treated with 
RT together with irradiated MOC2 cells (figure 7D). 
We observed a trend toward cell death when these cells 
were incubated in the presence of IL-2 and anti- CD137 
compared with IL-2 and matching isotype control anti-
body (figure 7E). These results suggest that Tregs convert 
to an effector phenotype in MOC2 tumors after RT+ 
anti- CD25+ anti- CD137 treatment. Importantly, genetic 
ablation of these Tregs reversed the tumor growth delay 
conferred by anti- CD137 (figure 6G).
dIsCussIon
Improving patient response to RT through use of 
currently available immunotherapies remains a tenuous 
goal for the field of oncoimmunology. Although RT trig-
gers inflammatory signals that involve both innate and 
adaptive immune responses,25 the negative feedback loop 
that follows this inflammatory response can contribute 
to immunosuppression in this context. Resistance to RT 
and checkpoint blockade has been identified as being 
mediated through upregulation of various markers, such 
as CTLA4, TIM3 and STAT3, known to enhance suppres-
sive functions of various immune populations.26 27 Here, 
we find that modulation of the DC- Treg axis in tumors 
resistant to RT+ immune checkpoint blockade acts 
within the TME to enhance antigen presentation in the 
lymph nodes and decrease Treg suppressive markers, 
reprogramming Tregs to exhibit cytotoxic function 
with retained Foxp3 expression after exposure to RT+ 
anti- CD25+ anti- CD137 therapy. The benefit of these 
reprogrammed Tregs is threefold: they coincide with a 
more activated DC (figure 4O), they express IFNγ and 
TNFα effector cytokines alongside increased Eomes 
(figure 4C,D,J) that are typically associated with T helper 
responses in promoting CD8 T cell function, and they 
express Perforin, suggesting potential cytotoxicity to the 
tumor (figure 7B). This not only suggests caution in the 
use of Foxp3 as the sole marker of inhibitory Tregs, but 
also identifies this combination approach as a mechanism 
of switching the dial from a tolerogenic to an inflamma-
tory TME and inducing a more therapeutically active 
phenotype of Treg with cytotoxic abilities. Finally, we 
show that only by hypofractionating the RT to maximize 
antigen presentation and enhance the immune response, 
tumor eradication is achieved when combined with down-
regulation of Treg suppression and enhancement of DC 
maturation, migration, and activation (figure 3F).
Although pharmacological depletion of Tregs in combi-
nation with RT yields tumor eradication in some models,8 
this does not appear to be an effective strategy across all 
immune cold, myeloid- enriched, HNSCC tumors. Based 
on the literature,28 we hypothesized that these monocytic 
and granulocytic myeloid populations are likely medi-
ators of resistance. However, targeting with anti- CSF1R, 
anti- CXCR2 or both, as previously used in other tumor 
models,28 or even with anti- Gr-1, failed to achieve any 
benefit in tumor growth delay when combined with RT or 
RT +anti- CD25. CSF1R, CXCR2 and even Gr-1 have been 
reported to be involved in the development of monocytic 
lineages that can also drive the development of DCs, both 
plasmacytoid and conventional.29–32 We therefore ratio-
nalized that we might be decreasing antigen presenta-
tion ability in this tumor model, especially in light of our 
results that anti- CD25 failed to stimulate CD103+ DCs in 
the tumor or lymph nodes. Considering that DCs are one 
target of suppression by Tregs,21 33 CD137 agonism was an 
attractive option as it has been documented to both repro-
gram Tregs21 as well as suppress CD137L reverse signaling 
that may inhibit CD103+ DC differentiation,22 solving the 
issues of both persistent presence of Foxp3+Tregs as well 
as lack of CD103+ DC stimulation.
We find that activation of DCs and induction of their 
ability to mature and migrate—not just their mere pres-
ence or ability to withstand RT—is critical to the response 
to radioimmunotherapy. Only with the addition of anti- 
CD137 to RT+ anti- CD25 do we see an increase in MHC- 
II+ DCs in the lymph nodes and increases in CD80 and 
CCR7 expression on MHC- II+CD103+ DCs. Blair et al34 
recently demonstrated that CD103+ DCs that survive RT 
were shown to exhibit higher levels of maturity markers 
such as CCR7 and CD80, but only in tumors they deemed 
radioimmunogenic. They noted that in poorly radioim-
munogenic tumors, they could rescue RT- mediated acti-
vation of CD103+ DCs in the tumor DLNs using Poly:IC 
administration. Although they were able to stimulate 
CD103+ DCs in one poorly radioimmunogenic model, 
Panc02- SIY, our data show no benefit in the addition 
of TLR agonism in another poorly radioimmunogenic 
model, MOC2, suggesting that in this model, resistance 
cannot be reversed with DC agonism monotherapy alone. 
It must rather be supplemented with targeting of immu-
nosuppressive Tregs. Here, we show a dual benefit of anti- 
CD137 to enhance DCs and reprogram Tregs.
Modulating the CD137- CD137L interaction in combina-
tion with RT +anti- CD25 contributed to significant destabi-
lization of Tregs, reprogramming them into Foxp3+CD4+ 
T cells with cytolytic activity. Using anti- CD137 agonist to 
turn on the cytolytic program in Tregs has been previ-
ously shown in virally driven tumors.21 Here, we demon-
strate a similar feature in poorly immunogenic tumors 
in the context of RT. This is likely partially induced by 
CD137 signaling on Tregs, as supported by our findings 
that a subpopulation of Foxp3+ Tregs transferred into RT 
+anti- CD25+anti- CD137 -treated RAG1–/– mice upreg-
ulate the expression of IFNγ, TNFα and Eomes. In the 
immunocompetent C57BL/6 MOC2 model, we observed 
significant reductions in NRP-1 and coinhibitory marker 
CTLA4, as well as the same increases of IFNγ and TNFα 
on Tregs as in the RAG1–/– transfer experiment. NRP-1 
expression on Tregs is a known correlate of poor prog-
nosis that has been shown to be a critical player in Treg 
fragility.13 Consistent with this study, the inflammatory 
environment triggered by increase in IFNγ and TNFα 
in the serum and on T cells and Tregs, along with this 
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decrease in NRP-1, contributes toward this state that they 
describe as intratumorous Treg fragility.13
Suppressive Tregs have been shown to interact with 
tumor- associated DCs and inhibit their function.35–37 
When Tregs are destabilized (eg, by disruption of 
pAKT, PI3K), the endogenous tumor- associated DCs 
can become highly activated following chemotherapy or 
immunotherapy.38 In one such model, the TME became 
dominated by immunogenic DCs that cross- presented 
tumor antigens and reactivated anergic T cells.39 Because 
cross- presentation of endogenous tumor antigens is 
dependent on the DC population in the tumor and its 
DLNs, removing Treg- mediated suppression of these 
DCs might enhance response to tumor antigens. In our 
model, we observe that the combination treatment RT 
+anti- CD25+anti- CD137 does indeed switch the DC to 
induce their maturation, migration, and activation as 
evidenced by the increase in CD80 and CCR7 on MHC- 
II+CD103+ DCs in the tumor DLNs. This requirement of 
DCs for anti- CD137’s ability to induce a T cell dependent 
response was evident by using BATF3–/– mice. In this 
model where CD8α+ cross- presenting DCs are genetically 
ablated, we observed no tumor growth delay, and poor 
infiltration of conventional CD4 and CD8 T cells when 
RT +anti- CD25+anti- CD137 was used in this model. Simi-
larly, in the DEREG model, the use of DT appeared to 
have a deleterious effect on CD8 T cell infiltration. The 
observed increase when wildtype tumor- bearing mice 
were treated with RT +anti- CD25+anti- CD137 was effec-
tively reversed when DT was substituted for anti- CD25 
in the triple combination therapy in DEREG mice. This 
underscores the DC- Treg as an axis for anti- CD137’s 
action in the context of RT and anti- CD25.
Finally, the importance of enhanced antigen release is 
supported with data showing that hypofractionated RT 
was required for tumor eradication. Adding anti- PD- L1 or 
Poly:IC failed to achieve similar results or add any further 
benefit. These data suggest that maximal antigenic stimu-
lation is achieved with hypofractionated RT, downregula-
tion of Treg suppressive markers (such as CD69, CTLA4 
and NRP-1) is achieved with anti- CD25, and enhancement 
of DC maturation, migration, and activation is achieved 
with the addition of anti- CD137. Any two of these three 
agents appear insufficient on their own in establishing 
tumor growth delay (or eradication) or reprogramming 
the DC- Treg axis.
In conclusion, these data represent an important thera-
peutic strategy in combating immune cold HNSCCs, which 
like the tumor models studied, are often HPV- negative, 
poorly T cell -infiltrated tumors of the oral cavity.1 We 
show that Tregs remain critical players in these myeloid- 
rich, cold, poorly immunogenic tumors but that over-
coming their immunosuppressive action, in the context 
of RT, requires TME reprogramming. We show that this 
reprogramming is achievable by using combination 
RT+anti- CD25+anti- CD137, where each component of the 
therapy appears critical to enhancing an element of the 
immune cycle. The end result of this combination is a TME 
sustained in a more inflammatory and less tolerogenic 
state. We provide evidence that stimulation with combi-
nation of hypofractionated RT+anti- CD25+anti- CD137 
induces the production of cytolytic molecules in Tregs 
while enhancing maturation and migration of DCs to the 
lymph nodes leading to T cell priming.
MetHods
Cell lines and cell culture
Murine MOC2 and LY2 squamous cell carcinoma cell 
lines were used for in vivo studies. The MOC2 cell line 
obtained from Ravindra Uppaluri (Dana- Farber Cancer 
Institute) was derived from a C57Bl/6 mouse that devel-
oped SCC after exposure of the oral cavity to DMBA 
over 25 weeks. The LY2 cell line obtained from the lab 
of Nadarajah Vigneswaran (University of Texas Health 
Science Center) was derived from lymph node metas-
tases that developed in BALB/c mice after inoculation 
of PAM 212 squamous cell carcinoma cells.40 Both lines 
exhibit wildtype expression of TP53 and EGFR. All 
cells were cultured at 37°C and 5% CO2 in appropriate 
media; DMEM- F12 supplemented with 10% FBS and 1% 
primocin/fungin (InvivoGen, San Diego CA) for LY2 
and DMEM F12: IMDM (1:2) supplemented with 10% 
FBS and 1% primocin/fungin (InvivoGen, San Diego, 
California, USA), 1.75 µg EGF, 20 µg hydrocortisone, and 
0.1% insulin solution (human) (Sigma Aldrich, St. Louis, 
Missouri, USA) for MOC2.
Animal tumor models
Orthotopic HNSCC models were established as previ-
ously described.5 Briefly, cell suspensions were mixed 
with equal volumes of Matrigel (10 mg/mL, BD Biosci-
ences, San Jose, California, USA) and injected submu-
cosally into the buccal mucosa at a final concentration 
of 1×106/0.1 mL per animal for LY2 cells, 1×105/0.1 mL 
per animal for MOC2 cells in C57Bl/6 and DEREG mice, 
and 1×106/0.1 mL per animal for MOC2 cells in BATF3–
/– mice. BALB/c (Charles River, Wilmington MA) and 
C57Bl/6 ((Jax Labs, Bar Harbor, Maine, USA)) mice 
were used for LY2 and MOC2 cell lines, respectively. 
Mice with a diphtheria toxin receptor- eGFP gene under 
the control of the FOXP3 promoter, or DEREG mice,41 
on a C57Bl/6 background, were obtained through a 
collaborator (Edward Chan). BATF3–/– mice,42 deficient 
for CD8α+ cross- presenting DCs on a 129S background, 
were obtained through a collaborator (Beth Tamburini). 
Treatment was started when average tumor size reached 
100 mm3 (6–8 days postinoculation). Tumor size was 
measured twice weekly with digital calipers and tumor 
volumes were estimated using the formula (V=A×B2/2 
mm3), where A and B are the longer and shorter diam-
eters of the tumor, respectively. Mice exhibiting signs of 
morbidity according to the guidelines set by the Institu-
tional Animal Care and Use Committee (IACUC) were 
sacrificed immediately. Primary tumors and tumor DLNs 
were harvested on sacrifice. All protocols for animal tumor 
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models were approved by the IACUC of the University of 
Colorado, Denver.
Antibodies and drugs
All antibody- based treatments were accompanied by the 
isotype equivalent as a control. For antibody depletion 
experiments, anti- CD25 (Clone: PC-61.5.3, Bio X Cell, 
Lebanon, New Hampshire, USA), Fc- optimized anti- 
CD25 (Clone: PC61, Evitria AG, Schlieren, Switzerland) 
anti- CD4 (Clone:GK1.5, Bio X Cell, Lebanon NH), anti- 
CD8a (Clone:53–6.7, Bio X Cell), anti- CD137 (4- 1BB, 
Bio X Cell) (Clone:3H3, Bio X Cell, Lebanon NH) and 
anti- PD- L1 (10F.9G2, Bio X Cell) injected I.P at 10 mg/
kg/dose twice weekly for the length of each experiment. 
For experiments using upfront anti- CD25 administered 
before implantation, Bio X Cell anti- CD25 antibody was 
used; for experiments using anti- CD25 concurrent with 
RT, Fc- optimized anti- CD25 antibody was used. Isotypes 
were used at the same dose, and in the same time frame. 
Diphtheria toxin (DT) was administered I.P. twice weekly 
to DEREG mice at a dose of 1 µg/mouse as previously 
reported.41 Poly:IC was administered at 10 ug in 30 uL 
intratumorally four times per week. Fingolimod hydro-
chloride (FTY720) (Cayman Chemical, Ann Arbor, Mich-
igan, USA) was given at a dose of 2 mg/kg three times per 
week administered I.P.
Irradiation
RT was performed using the X- RAD SmART image- guided 
irradiator (Precision X- Ray, Branford CT) at 225kVp, 
20mA with 0.3 mm Cu filter. During mouse buccal RT, 
mice were anesthetized with isoflurane and positioned in 
the prone orientation. CBCT scans of representative mice 
were acquired and Monte- Carlo simulations performed 
using SmART- ATP software (SmART Scientific Solutions, 
Maastricht, The Netherlands) to validate treatment plans. 
Mice were positioned using fluoroscopy to ensure accu-
rate targeting prior to RT delivery at a dose rate of 5.6 Gy/
min.
statistical analysis
Statistical analysis was completed using one- way anal-
ysis of variance with Tukey correction for all compar-
isons with three or more groups and unpaired t- tests 
(two tailed) were used for all comparisons involving two 
groups with other tests used where described. For survival 
analysis, Kaplan- Meier curves were analyzed based on the 
log- rank (Mantel- Cox) test for comparison of all groups. 
All statistical analyses were performed in Prism soft-
ware (GraphPad, V.8.4.2) or R programming language 
(V.3.6.1).
Figures
Figure 7D was created with  BioRender. com.
Flow cytometry
Tumors were digested and strained into single- cell 
suspension. Briefly, tumors were finely cut and placed 
in Hanks' Balanced Salt Solution (HBSS) containing 
200U of Collagenase III (Worthington, Lakewood, New 
Jersey, USA) for 40 min at 37°C with gentle shaking every 
15 min. After the incubation period, tumor pieces were 
passed through a 70 um nylon mesh. The resulting cell 
suspension was centrifuged and resuspended in red 
blood cell lysis buffer for 5 min (InVitrogen, Carlsbad, 
California, USA). HBSS was added to inactivate RBC lysis 
buffer, cell suspensions were centrifuged, resuspended 
and counted using an automated cell counter. DLNs 
were also collected where described and processed into 
single- cell suspensions through mechanical separation. 
For intracellular flow cytometric analysis, 2×106 live cells 
were plated in 6- well plates and cultured for 4 hours in 
the presence of monensin to prevent release of cytokines 
and PMA and ionomycin to stimulate cytokine produc-
tion. After the incubation period, cells were incubated 
with a live/dead aqua viability stain kit (Invitrogen, 
Carlsbad, California, USA) for 30 min at 4°C. Cells were 
centrifuged then incubated with Fc block (anti- CD16/32 
antibody) (Tonbo Biosciences, San Diego CA) for 20 min 
at 4°C Cells were centrifuged and resuspended in buffer 
containing staining antibodies and incubated at 4°C for 
20 min. For analysis of immune cells, the following conju-
gated antibodies were used: PerCP- CD45 (Clone: 30- F11 
BD Biosciences), BUV395- CD3 (Clone: 145-2 C11 BD 
Biosciences), PercP/Cy5.5- CD3 (Clone: 145-2 C11 BD 
Biosciences) SuperBright436- CD4 (Clone: GK1.5 Invit-
rogen), BrilliantBlue515- CD8 (Clone: 53-6.7 BD Biosci-
ences), APC- CD137 (Clone: 17B5 Biolegend), PE- FoxP3 
(clone: MF-14 Biolegend), AF488- FoxP3 (Clone: MF-14 
Biolegend,), FITC- FoxP3 (Clone: 3G3 Millipore/Sigma), 
BV605 IFN-γ (Clone: B27 BD Biosciences), BV421- IFN-γ 
(Clone: B27BD Biosciences), efluor450- TNF-α (Clone: 
MP6- XT22Invitrogen), BV750 TNF-α(Clone: MP6- XT22 
BD Biosciences), BV785- CD69 (Clone: FN50 BD Biosci-
ences), BV711- CD25 (Clone: PC-61 BD Biosciences) 
BV605- CD25 (Clone: PC-61 BD Biosciences), APC- PD-1 
(Clone: RMP1-30 BD Biosciences), PE/Cy7- NK1.1 (Clone: 
PK136 BD Bioscience), PE/Dazzle594- TIM3 (Clone: 7D3 
BD Biosciences), PerCP/Cy5.5- CTLA4 (Clone: BNI3 BD 
Biosciences), FITC- TIGIT (Clone: GIGD7 Invitrogen), 
PE/Cy7- NRP-1 (Clone: 3E12 Biolegend), BV711- CD154/
CD40L (Clone: MR1 BD Biosciences), AF700- SEMA4A 
(Clone:757129, R&D Systems), BV421- Tbet (Clone: 
04–46 Biolegend), FITC- Granzyme- B (Clone: GB11 BD 
Biosciences), efluor450- EOMES (Clone: Dan11Mag 
Invitrogen), BUV737- CD11b (Clone: M1/70 BD Biosci-
ences), APC- CD11c (Clone: HL3 BD Biosciences), APC/
Cy7- F4/80 (Clone:BM8 Biolegend), AF488- iNOS (Clone: 
CXNFT Invitrogen), PE/Dazzle594- CD103 (Clone: 
2E7 Biolegend), PE- CD137L (Clone: TKS1 Biolegend), 
BV421- MHC- I (Clone: 28-8-6 BD Biosciences), BV650- 
I- Ab (Clone: M5/114 BD Biosciences), BV480- CD80 
(Clone: 16- 10A1 BD Biosciences), PE/Cy7- PD- L1 (Clone: 
10F.9G2 Biolegend), PercP efluor710- PD- L1 (Clone: 
MIH5 ebiosciences) efluor450- Ly6C (Clone: HK1.4 
Invitrogen), BV785- Ly6G (Clone: 1A8 BD Biosciences), 
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PerCP/Cy5.5- CCR7 (Clone: 4B12 Biolegend, San Diego 
CA), AlexaFluor647- PTEN (Clone: A2B1 BD Biosci-
ences), BV421- pAKT (Clone: M89-61 BD Bioscience), 
PE- pi3K (Clone: PI3KY458- 1A11 Invitrogen) Brilliant-
blue700- PD-1 (Clone: RMP1-30 BD Biosciences), 
BV480- PD-1 (Clone: J43 BD Biosciences), PE- Perforin 
(Clone: S16009A Biolegend San Diego CA) BV750- GR-1 
(Clone: RB6- 8C5 BD Biosciences). Flow cytometry 
samples were analyzed on an Aurora spectral cytometer 
(Cytek Biosciences) or a Yeti cell analyzer (Propel Labs) 
through The University of Colorado Cancer Center Flow 
Cytometry Shared Resource.
time of flight cytometry
Tumors for CyTOF were prepared as single cell suspen-
sion as described above. For LY2 tumor- bearing mice, 
10 Gy RT was performed 11 days post- implantation 
when tumors reached average volumes of approximately 
100 mm3. For MOC2 tumor- bearing mice, 10 Gy RT 
was performed 10 days post- implantation when tumors 
reached average volumes of approximately 100 mm3. Irra-
diated LY2 and MOC2 tumors were collected 4 and 3 days 
post- RT, respectively. Barcoding was performed with the 
Cell- ID 20- Plex Barcoding Kit (Fluidigm, South San Fran-
cisco, California, USA) on combined LY2 samples sepa-
rately on combined MOC2 samples to enable consistent 
analysis of fluorescence between samples. Cell surface 
staining was performed with the Maxpar Cell Surface 
Staining kit (Fluidigm), phospho- protein staining was 
performed with the Maxpar Phospho- Protein Staining 
kit (Fluidigm) and intracellular marker staining was 
performed with the Maxpar Nuclear Antigen Staining 
kit (Fluidigm). Panels for staining using Maxpar anti-
bodies are provided in online supplemental tables 2 and 
3 Samples were analyzed with the Helios Mass Cytometer 
through The University of Colorado Cancer Center Flow 
Cytometry Shared Resource. Debarcoding analysis was 
performed with the Single Cell Debarcoder standalone 
application (R2013b 8.2. for Mac, Nolan Laboratory, 
Stanford University) with a Mahalanobis cut- off of 30 and 
a separation cut- off of 0.1.
Flow and CytoF analysis
Analysis of flow cytometry and CyTOF data was performed 
with Flowjo software (V.10.6.2, Flowjo, Ashland, Oregon, 
USA). Fluorescence minus- one controls were using to 
determine gating strategy for flow cytometry experi-
ments, and positive controls using splenocytes were used 
to determine gating for CyTOF experiments.
Plots using t- Distributed Stochastic Neighbor Embed-
ding (t- SNE) were created with R programming language 
(V.3.6.1) using the cytofkit package (V.1.11.3). Sample groups 
were gated for CD45+ singlets and concatenated for input 
to cytofkit. Parameters used were transformation method 
cytofAsinh, Rphenograph_k value 30, t- SNE perplexity 30, 
t- SNE max iterations 2000, FlowSOM_k 40, visualization 
method t- SNE, and cellular progression NULL.
rnA-seq
Tumors for RNA- Seq analysis were harvested and 
immediately frozen in liquid nitrogen. Frozen tumors 
were stored at –80°C until time of analysis. RNA from 
tumors was harvested using an RNA miniprep kit (Zymo 
research, Irvine CA). Sequencing and library prep were 
performed by The Genomics and Microarray Shared 
Resource at University of Colorado Denver Cancer 
Center. PolyA selection was used for library prep and 
sequencing was performed on an Illumina NovaSEQ 
6000 with 2×150 paired end reads at a depth of 20 million 
reads per sample.
Illumina adapters and the first 12 base pairs of each 
read were trimmed using BBDuk (BBMap - Bushnell B. 
-  sourceforge. net/ projects/ bbmap/), and reads <50bp 
post- trimming were discarded. Reads were aligned and 
quantified using STAR (2.6.0a)43 against the Ensembl 
mouse transcriptome (mg38.p6 genome (release 96)). 
Lowly expressing genes were removed if mean raw 
count <1 or mean counts per million (CPM) <1 for the 
dataset. Reads were normalized to CPM using the edgeR 
R package.44 Differential expression was calculated using 
the voom function in the limma R package.45 Gene set 
enrichment analysis was performed using the full ranked 
list of genes by fold change for the indicated compar-
ison and the fgsea R package46 using Hallmark gene sets 
from the Molecular Signatures Database.24 A heatmap 
was generated with the ComplexHeatmap R package 
following z- score transformation.47
Magpix cytokine analysis
Terminal bleeds were taken via heart stick on sacrifice. 
Serum from blood samples was acquired by collecting 
blood in BD microtainers (BD Biosciences) and incu-
bating for 30 min at room temperature. Tubes were centri-
fuged at 6000 RPM for 2 min and serum was collected and 
stored at –80°C until time of analysis. Serum was subjected 
to a custom Magpix cytokine analysis kit (Luminex, Austin 
Texas, USA). All protocols were run as per manufactur-
er’s instructions. Magpix plate analyzed using a Magpix 
plate reader available through The University of Colo-
rado Cancer Center Flow Cytometry Shared Resource.
Adoptive transfer of tregs
Spleens and lymph nodes of donor DEREG mice harvested 
and Tregs were first isolated with an EasySep Mouse CD4+ 
T cell Isolation Kit (Stemcell, Cambridge, Massachusetts, 
USA) and then sorted using GFP signal encoded on the 
FOXP3 promoter on a Sony MA900 through The Univer-
sity of Colorado Cancer Center Flow Cytometry Shared 
Resource. Cells were combined and 5.0×105 live Tregs 
were injected via tail vein into recipient RAG1–/– mice 
with previously established and irradiated MOC2 buccal 
tumors. Recipient mice were sacrificed 9 days after adop-
tive transfer and tumors and lymph nodes were harvested 
for flow cytometric analysis.
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treg cytolytic assay
Spleens, tumors and tumor DLNs were harvested from 
MOC2 tumor- bearing DEREG mice 8 days post- treatment 
with 10 Gy RT. Samples were processed to single cell suspen-
sion in same method as above flow cytometry samples. Total 
T cells and Tregs were first isolated with an EasySep Mouse 
T Cell Isolation Kit (Stemcell) and then sorted using GFP 
signal encoded on the FOXP3 promoter on a Beckman 
Coulter MoFlo XDP70 cell sorter through The University of 
Colorado Cancer Center Flow Cytometry Shared Resource. 
MOC2 cells were cultured and irradiated with 10 Gy and 72 
hours later were stained with Cell Tracker Deep Red (Invit-
rogen) before being combined with sorted Tregs with a 2:1 
ratio of Tregs to MOC2 cells with the irradiated conditioned 
media. Tregs and MOC2 cells were incubated at 37°C for 
4 hours in the presence of mouse IL-2 recombinant protein 
(Invitrogen) at 2 ug/mL and anti- CD137 (4- 1BB, Bio X 
Cell) (Clone:3H3, Bio X Cell) or isotype equivalent control 
(rat IgG2a isotype control, antitrinitrophenol)(Clone:2A3, 
Bio X Cell) at 10 ug/mL. Samples were stained with a live/
dead aqua viability stain kit (Invitrogen) for 30 min at 4°C 
and then analyzed on an Aurora spectral cytometer (Cytek 
Biosciences, Fremont, California, USA). Representative 
gating is shown in online supplemental figure 9.
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